Carla Grandori

Carla Grandori

Company: SEngine Precision Medicine

Job title: CEO


Dr. Grandori career started with a degree in Medicine from the University of Rome and subsequently a PhD in Biochemistry and Molecular Biology from The Rockefeller University focused on tyrosine kinase oncogenes with Dr. Hanafusa, a founder of the field.  In 1991, Dr. Grandori joined the Fred Hutchinson Cancer Research Center (FHCRC) studying the transcriptome of the MYC oncogene and later established a laboratory focused on the discovery of MYC-synthetic lethal gene pairs as future drug targets. In 2006 Dr. Grandori academic background was enriched by experience in the industry setting, from Rosetta Inpharmatics, a subsidiary of Merck, where a platform of high-throughput siRNA screening and novel bioinformatics tools were employed in drug discovery. In response to direct requests from cancer patients Dr. Grandori’s career took a sharp twist that led to the foundation of Cure First, a not-for-profit organization supporting functional genomics approaches in cancer research and in 2015 of SEngine Precision Medicine, a biotech that merges functional precision medicine diagnostics with drug discovery. Dr. Grandori is currently CEO of SEngine Precision Medicine.

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.